Peter Maslak
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Peter Maslak as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:49 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01266083 · WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)Sellas Life Sciences Group · completed · Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT00528450 · Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic LeukemiaMemorial Sloan Kettering Cancer Center · terminated · Leukemia · principal investigator
- Ph2NCT00002567 · High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in RemissionMemorial Sloan Kettering Cancer Center · completed · Bone Marrow Ablation, Leukemia · study chair
- Ph2NCT00002800 · Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic SyndromeMemorial Sloan Kettering Cancer Center · completed · Leukemia, Myelodysplastic Syndromes, Neutropenia · study chair
- Ph2NCT00006019 · Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate CancerMemorial Sloan Kettering Cancer Center · completed · Leukemia, Lung Cancer, Lymphoma · study chair
- Ph1NCT00006040 · Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory LeukemiaMemorial Sloan Kettering Cancer Center · completed · Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- INHIBITION OF HISTONE DEACETYLASE AS ANTI CANCER THERAPYR01CA082740 · NCI · SLOAN-KETTERING INST CAN RESEARCH · fiscal years 2001 to 2002 · $261,421 awarded in 2002Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA008748 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ALEX MACDONALD · fiscal years 2011 to 2026Named on NCT00528450
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:49 UTC. The ranking covers the 200 most relevant of 23 PubMed records, and a shared surname and initials can bring in a namesake. All 23 on PubMed
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.N Engl J Med · 20182,262 citationsRCR 73.0
- CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.Sci Transl Med · 20131,702 citationsRCR 43.5
- 1,087 citationsRCR 23.5
- Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.J Clin Oncol · 2001160 citationsRCR 3.0
- Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.Blood Adv · 2018136 citationsRCR 4.2
- Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.J Clin Oncol · 2002129 citationsRCR 2.4
- 124 citationsRCR 2.7
- Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.Clin Cancer Res · 2008115 citationsRCR 2.3
- Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience.Leukemia · 1994109 citationsRCR 2.4
- 107 citationsRCR 3.5